« Return to News | CROs/Service Providers

Variance makes growth investment in Veristat

Friday, January 25, 2013 09:56 AM

Holliston, Mass.-based CRO Veristat said Variance Development Partners, a private investment group focused on contributing growth capital to small to mid-sized firms serving developing pharmaceutical and medical device companies, has made a growth equity investment in the company.

Veristat has 20 years of expertise supporting clinical trials for pharmaceutical, biotechnology, and medical device companies. Its services include trial design, biostatistics, statistical programming, medical writing, clinical monitoring and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings.

“Many developing CROs are filled with scientific talent which routinely gets distracted from maximizing their client impact by the need to manage their business. Our partnership will allow Veristat to focus its scientific expertise,” said Patrick Flanagan, managing partner with Variance.

Comprised of executives from the pharmaceutical and financial industries, Variance invests in promising companies in the life sciences marketplace to help fuel growth strategies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.